Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.4K
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.1K
Coagulation01:09

Coagulation

6.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Antiplatelet Strategies and the Unfinished Story of Thrombosis Prophylaxis.

Circulation research·2026
Same author

Bridging the Gap in AL and ATTR Cardiac Amyloidosis: Integrating Histopathology, Biomarkers, and Multimodal Imaging for Subtype-Specific Diagnosis.

Reviews in cardiovascular medicine·2026
Same author

Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction.

Circulation·2025
Same author

Cardiac Amyloidosis in the Real World: Clinical Presentations, Disease Overlap, and Therapeutic Imperatives.

Reviews in cardiovascular medicine·2025
Same author

Genetic and Clinical Characterization of a Large Cohort with Suspected Monogenic Stone Disease.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Relationship Between Atrial Dysfunction and Atrial Arrhythmias in Adults With Fontan Palliation: Role of Atrial Strain Imaging.

Journal of the American Heart Association·2025
Same journal

Multi target effects of Allium macrostemon against myocardial infarction: an integrated network pharmacology, molecular docking, and experimental study.

Journal of thrombosis and thrombolysis·2026
Same journal

Comparative effectiveness of figure-of-eight suture and manual compression for femoral venous hemostasis after atrial fibrillation ablation: A grade assessed meta-analysis.

Journal of thrombosis and thrombolysis·2026
Same journal

Tissue factor-related biomarkers during combined androgen blockade in patients with prostate cancer: A brief report.

Journal of thrombosis and thrombolysis·2026
Same journal

Opioid use disorder and clinical outcomes following percutaneous coronary intervention for acute coronary syndromes.

Journal of thrombosis and thrombolysis·2026
Same journal

Sex-based differences in clinical outcomes among cardiogenic shock patients treated with mechanical circulatory support.

Journal of thrombosis and thrombolysis·2026
Same journal

IGF-1 axis: The signalling bond in cancer-associated thrombosis and cachexia?

Journal of thrombosis and thrombolysis·2026
查看所有相关文章

相关实验视频

Updated: Jun 28, 2025

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.3K

因素XI:结构,功能和治疗抑制.

Ahmed E Ali1, Richard C Becker2

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Journal of thrombosis and thrombolysis
|April 15, 2024
PubMed
概括
此摘要是机器生成的。

XI因子 (FXI) 抑制剂代表了一种有前途的新型抗凝剂类别,与现有疗法相比,可以通过降低出血风险提供更好的安全性. 目前正在进行广泛的临床试验,以确认它们在预防血栓形成方面的有效性和最佳使用.

关键词:
心房动是一种心房动.第十一因子抑制剂 抑制剂缺血性中风是因为缺血性中风.研究和开发新的抗凝剂.

更多相关视频

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

778

相关实验视频

Last Updated: Jun 28, 2025

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.3K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

778

科学领域:

  • 心血管医学 心血管医学
  • 血液学 血液学 血液学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 血栓栓塞栓症仍然是一个重大的全球健康负担,需要有效的抗凝血治疗.
  • 目前的抗凝血剂 (肝素,VKA,DOAC) 携带出血风险,推动寻找更安全的替代品.
  • 本质凝血途径,特别是XI因子 (FXI),是新型抗凝血剂的有希望的目标,其安全性可能会得到改善.

研究的目的:

  • 审查开发FXI抑制剂作为更安全的抗凝固剂的理由.
  • 介绍目前正在开发中的先进的FXI抑制剂.
  • 总结临床试验数据和FXI抑制剂的持续研究.

主要方法:

  • 关于FXI缺乏和抑制的临床前研究和流行病学数据的审查.
  • 分析了2期临床试验的结果,涉及各种指示 (骨科手术,心房动,ESRD,MI,中风).
  • 评估各种FXI向策略,包括寡核酸,抗体,小分子,和体.

主要成果:

  • 临床前和流行病学数据表明,FXI抑制可以降低出血风险并提供抗血栓保护.
  • 第二阶段研究表明,FXI抑制剂在各种临床环境中具有有希望的疗效.
  • 多种FXI抑制剂处于临床开发的各个阶段,证明了可行性.

结论:

  • 与传统疗法相比,FXI 抑制剂是一种潜在的更安全的抗凝剂策略.
  • 通过大规模的第三期试验进行进一步验证至关重要,以建立有效性和安全性之间的最佳平衡.
  • 目前正在进行的研究和计划中的试验旨在确定FXI抑制剂在各种血栓状况中的临床作用和最佳应用.